Stock events for Precigen, Inc. (PGEN)
The past six months have seen several significant events impacting Precigen, Inc.'s stock price. The FDA approval of PAPZIMEOS and its subsequent commercialization provided upward support for the stock. Despite revenue growth, financial challenges and insider selling acted as headwinds. Analyst sentiment is mixed, with a consensus "Hold" rating. The stock has experienced significant price fluctuations. Patient Capital Management, LLC, was a top contributor to the company's strategy in Q4 2025 following the early approval of PAPZIMEOS.
Demand Seasonality affecting Precigen, Inc.’s stock price
Specific patterns of demand seasonality for Precigen, Inc.'s products and services are not detailed. Demand is likely driven by medical need, clinical trial progress, and regulatory approvals rather than typical consumer-driven seasonal fluctuations.
Overview of Precigen, Inc.’s business
Precigen, Inc. is a biotechnology company focused on developing next-generation gene and cellular therapies within the Healthcare sector. They develop synthetic biology solutions and gene programs. Key products and platforms include PAPZIMEOS, the AdenoVerse platform, the UltraCAR-T platform, UltraVector platform, mbIL15, Sleeping Beauty, AttSite recombinases, RheoSwitch, kill switches, tissue-specific promoters, the ActoBiotics platform, and Exemplar Genetics LLC.
PGEN’s Geographic footprint
Precigen, Inc. is headquartered in Germantown, Maryland, United States. The company conducts its research and development, and manufacturing operations, in both the United States and Europe.
PGEN Corporate Image Assessment
Precigen's brand reputation has been bolstered by the FDA approval and commercialization of PAPZIMEOS, positioning the company as a leader in recurrent respiratory papillomatosis (RRP). The rapid commercialization momentum further enhances its reputation. Significant insider selling could potentially be perceived negatively by some investors.
Ownership
Precigen, Inc. has a diverse ownership structure, including institutional, retail, and individual investors. Major institutional shareholders include Patient Capital Management, LLC, BlackRock, Inc., and others. Randal Kirk is a significant individual investor and insider.
